Federal Trade Commission accuses three drug middlemen of inflating insulin prices
In a lawsuit, the FTC accused Optum Rx, Caremark and Express Scripts of creating "a broken rebate system that inflated insulin drug prices, boosting PBM (prescription drug benefit managers) profits at the expense of vulnerable patients.
Sen. Mike Braun has a unique opportunity to hold Novo Nordisk accountable for discontinuing insulin drug Levemir.
Ypsomed reports positive outcomes from a randomized trial of its closed-loop insulin delivery technology during type 1 ...
MADRID — The de-escalation of a multiple daily injection regimen of insulin for type 2 diabetes to a once-daily fixed-ratio combination of insulin glargine U100 and glucagon-like peptide 1 ...
WASHINGTON, September 23, 2024--(BUSINESS WIRE)--AIDS Healthcare Foundation (AHF) applauds the U.S. Federal Trade Commission (FTC) for taking decisive action against pharmacy benefit managers (PBMs) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback